AM805 / Amlogenyx - LARVOL DELTA

Amlogenyx Announces Positive Preclinical Data on AM805, a Potent Amyloid-Degrading Protease for the Treatment of Alzheimer’s Disease (GlobeNewswire) - "The data will be presented in a poster session, taking place March 19-21, and in an ePoster at the AD/PD 2026 International Conference....Study results showed that all routes of dosing resulted in increased PPCA activity and reduced amyloid-positive brain area in a dose-dependent manner in mouse models of both severe and moderate Alzheimer’s disease. The magnitude of reduction achieved was comparable to, and in some cases exceeded, that reported for approved Alzheimer’s disease monoclonal antibodies....The Company plans to pursue an Investigational New Drug (IND) application submission to the U.S. Food and Drug Administration for AM805 in 2027."

IND • Preclinical • Alzheimer's Disease